Patients with indicators of high-risk or established ASCVD, chronic kidney disease, or heart failure According to the ADA, when considering an agent for add-on to metformin background therapy, the first recommended consideration is whether or not the patient has indicators of high-risk or established ASCVD, chronic kidney disease (CKD), or heart failure ( Figure 2 )
Patients should mark the date on their pen when removing it from the fridge
Most side effects are mild and improve as your body adjusts to the medication
We surveyed over 800 out of our 6000+ customers
If you notice this, speak with your healthcare provider about adjusting your injection timing
We show that the novel, dual incretin analogue tirzepatide markedly improves while the GLP- 1R agonist liraglutide only preserves cardiac function and attenuates remodelling in an angiotensin-II infusion-induced cardiac injury model in mice